摘要
凝集素样氧化低密度脂蛋白受体1(LOX-1)是1997年被发现的氧化低密度脂蛋白(oxLDL)受体,属于E族清道夫受体家族,它可以结合、内化、降解oxLDL。LOX-1具有介导内皮细胞功能失调、平滑肌细胞凋亡、巨噬细胞泡沫化与炎症以及不稳定斑块的形成等功能。由此可见,LOX-1参与了动脉硬化发生发展的各个环节,有望成为动脉硬化性心血管疾病治疗的新靶点。近年来,可溶性LOX-1的检测有助于动脉硬化相关疾病的预防。本文对LOX-1的表达调控及其在动脉粥样硬化发生发展中的作用进行综述。
Lectin-like oxidized LDL receptor-1（LOX-1）,a newly identified vascular receptor for oxLDL,belongs to E-class scavenger receptor which is involved in the binding,internalization and degradation of oxLDL.LOX-1 also mediates several central events in atherosclerosis： endothelial dysfunction,the apoptosis of smooth muscle cells,macrophage-derived foam cell formation,inflammation and plaque rupture.Taken together,LOX-1 participates in each phases of the development of atherosclerosis and thus could be a potential therapeutic target for the management of atherosclerosis.Recently,soluble LOX-1 has been a useful diagnostic biomarker in atherosclerosis-related cardiovascular disorders.This paper reviews the regulation of LOX-1 and the crucial role of LOX-1 in the development of atherogenesis.
出处
《中国药理学与毒理学杂志》
CAS
CSCD
北大核心
2011年第4期402-406,共5页
Chinese Journal of Pharmacology and Toxicology
基金
国家自然科学基金资助项目(30472022)
国家科技部新药创制重大专项资助项目(2009ZX09401-307)
国家科技部新药创制重大专项资助项目(2009ZX09303-007)
国家科技部新药创制重大专项资助项目(2009ZX09102-152)
2010年教育部"博士研究生学术新人奖"资助项目~~
